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Remy Dulery,1 Julia Salleron,2 Anny Dewilde,3 Julien Rossignol,1 Eileen M. Boyle,1 Julie Gay,1
Eva de Berranger,1 Valerie Coiteux,1 Jean-Pierre Jouet,1 Alain Duhamel,1
Ibrahim Yakoub-Agha1This study investigated the impact of human herpesvirus type 6 (HHV6) reactivation within 100 days of
allogeneic stem cell transplantation (allo-SCT) on patient outcomes. HHV6 plasma loads were monitored
weekly by quantitative PCR. Of 235 consecutive patients, 112 (48%) had an early positive HHV6 PCR test
(group A) and 123 (52%) did not (group B). HHV6 reactivation was less frequent in patients who received
reduced-intensity conditioning (P 5 .028). In group A, only 6 patients (5%) were asymptomatic; the most
common clinical manifestations were fever (n5 60), skin rash (n5 57), diarrhea (n5 51), pulmonary com-
plications (n5 19), and neurologic disorders (n5 12). Comparedwith the patients in group B, those in group
A experienced delayed platelet engraftment (P5.003) and more frequent grade II-IV acute graft-versus-host
disease (GVHD) (47% versus 30% in group B; P5 .009). In multivariate analysis, the most important factors
influencing the development of grade II-IV acute GVHD development were early HHV6 reactivation (P5.03)
and unrelated donor status (P\.001). HHV6 reactivation adversely influenced 6-month survival (P 5 .04).
Of the 38 evaluable patients receiving antiviral treatment, 34 had a significantly decreased HHV6 load. Our
findings indicate that HHV6 reactivation after allo-SCT is associated with delayed platelet engraftment, early
posttransplantation mortality, and the development of acute GVHD. Careful monitoring of HHV6 by PCR is
warranted during the early posttransplantation period.
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Treatment, Real-time polymerase chain reactionINTRODUCTION
Human herpesvirus type 6 (HHV6) is a member of
the b herpesvirus subfamily [1,2]. Two distinct variants
of HHV6 have been identified, variants A and B, with
75%-95% nucleotide sequence identity. Variant B is
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6/j.bbmt.2011.12.579in immunocompromised hosts [3]. Primary HHV6
infection is recognized as the cause of exanthema sub-
itum and acute febrile illness. More than 90% of the
general population has been infected byHHV6,mostly
during early childhood. Only a few cases of infection or
reactivation in immunocompetent adults have been
reported. Like other herpesviruses, HHV6 remains
latent in host cells after the primary infection [4].
Few previous studies have addressed the impact
of HHV6 reactivation on the outcome of allogeneic
stem cell transplantation (allo-SCT). Furthermore,
interpretation of the existing (and often contradictory)
data is made difficult by the small numbers of patients
reported in published studies to date. HHV6 reactiva-
tion occurs in approximately one-half of allo-SCT
recipients,mainly during thefirstmonth posttransplan-
tation [5-8], and may cause interstitial pneumonia
[9-11] and encephalitis [12-14]. Reactivation also has
been associated with fever, skin rash [8,15], and
susceptibility to cytomegalovirus (CMV) disease [13].
The impact of HHV6 reactivation on the develop-
ment of acute graft-versus-host disease (GVHD) is
Biol Blood Marrow Transplant 18:1080-1089, 2012 1081HHV6 and Allo-SCTespecially controversial. Some studies have found an as-
sociation between HHV6 reactivation and acute
GVHD [6,16-18], whereas others have not [13,19-21].
Furthermore, little is known about the efficacy of
prophylactic or preemptive antiviral treatment in allo-
SCT recipients with HHV6 reactivation. With a view
toward better understanding the clinical significance
and management of HHV6 reactivation after allo-
SCT,we report a single-center study of 235 consecutive
patients who underwent allo-SCT in our transplanta-
tion unit.PATIENTS AND METHODS
Patients and Transplantation Modalities
This study was performed between January 2004
and July 2009 in accordance with institutional guide-
lines. All patients undergoing transplantation during
this period in our unit were included. The study pro-
tocol was approved by Lille University Medical Cen-
ter’s Institutional Review Board. In accordance with
the Declaration of Helsinki, written informed consent
to participate was provided by each patient. The initial
patient and donor characteristics are summarized in
Table 1.
The stem cell source was bone marrow (BM; n 5
127), peripheral blood stem cells (PBSCs; n 5 74), or
cord blood (CB; n5 34). None of the patients received
a T cell–depleted graft. One hundred fifty-five patients
received a myeloablative conditioning regimen, com-
prising 12 Gy of total body irradiation (TBI) plus
cyclophosphamide (n5 93) or busulfan plus cyclophos-
phamide (n 5 62). Eighty patients received reduced-
intensity conditioning (RIC), comprising fludarabine
plus TBI (2 Gy), fludarabine plus melphalan plus TBI
(2 Gy), or another fludarabine-based regimen (n 5
13). Depending on ongoing protocols, rabbit antithy-
moglobulin (ATG)at a dose of 2.5mg/kg/day for 2 con-
secutivedayswas used as part of someRICregimens and
some conditioning regimens for allo-SCT with CB or
unrelated mismatched donor grafts. Five of the 7 pa-
tients with aplastic anemia received ATG at a dose of
3.75 mg/kg/day for 5 days with cyclophosphamide.
The 2 remaining patients with aplastic anemia received
a different conditioning regimen because they had
chromosome 7 abnormalities. GVHD prophylaxis was
based on either cyclosporine plus a short course of
methotrexate (in patients receiving myeloablative con-
ditioning) or cyclosporine plus mycophenolate mofetil
(in patients receiving RIC). Recipients of CB grafts re-
ceived cyclosporine plus methylprednisolone (2 mg/
kg/day from day 1 post-SCT to day 12, then 1 mg/kg/
day from day 13 to day 19).
After conditioning, patients were treated in high-
efficiency particulate air-filtered facilities. Anti-
infective prophylaxis consisting of fluconazole 400mg once daily and oral valacyclovir 500 mg twice daily
was provided from day 9 before allo-SCT until post-
SCT discharge. Pneumocystis jirovecii and toxoplasmo-
sis prophylaxis consisted of sulfamide-based treatment
from day 9 before allo-SCT to the day of transplanta-
tion and then again from the day of neutrophil recov-
ery to day 100 post-SCT. Patients who experienced
febrile neutropenia received empiric broad-spectrum
i.v. antibiotics. Antifungal, antiparasitic, and antiviral
drugs were added as clinically indicated. To prevent
sinusoidal obstruction syndrome, all patients received
i.v. heparin 100 IU/kg until discharge [22]. Stress ul-
cers were prevented by omeprazole. Hemoglobin level
and platelet count were maintained above 8 g/dL and
10  109/L, respectively.
All patients were encouraged to eat a low-
microbial, highly controlled oral diet for as long as pos-
sible. A nasogastric feeding tube was inserted shortly
after transplantation, and overnight enteral nutrition
was administered. Acute GVHD was diagnosed and
graded according to standard criteria [23]. A detailed
history and physical examination were performed and
documented before the initiation of additional immu-
nosuppressive therapy. The physical examination in-
cluded a skin score, quantification of diarrhea, and
assessment of the patient’s mood and symptoms. If
acute gastrointestinal GVHDwas suspected, extensive
gastrointestinal examination and screening for infec-
tion were performed, as described previously [24]. En-
doscopic investigations (colonoscopy and/or upper
endoscopy with systematic biopsy or video-capsule en-
doscopy) were performed within 48 hours for each pa-
tient with diarrhea but without evidence of stage II or
higher acute GVHD-related skin lesions. Systematic
investigations included bacterial stool culture plus test-
ing for Clostridium difficile toxin; serum PCR analysis
for HHV6, Epstein-Barr virus (EBV), CMV, and ade-
novirus; and viral cultures of throat, stool, and urine
samples.
HHV6 reactivation was treated off-label with gan-
ciclovir or foscarnet. The choice of antiviral therapy
was based solely on the respective safety profiles of
each drug, given the lack of solid recommendations
in the literature regarding these drugs’ efficacy against
HHV6. Only symptomatic patients were treated.
Of note, patients with atypical GVHD-like clinical
features but no life-threatening symptoms received
antiviral treatment alone before initiation of any addi-
tional immunosuppressive treatment, whereas patients
with ongoing GVHD and subsequent HHV6 reactiva-
tion were treated with both antiviral and immunosup-
pressive drugs.
Specimen Collection
Weekly monitoring of EBV, CMV, HHV6, and
adenovirus serum loads was initiated within the first
month after transplantation. After discharge, the
Table 1. Patient Characteristics and Risk Factors for HHV6 Reactivation
Total Group A Group B P
Number of patients (%) 235 (100) 112 (48) 123 (52)
Recipient age, years, median (range) 42.2 (2.6-62.6) 41.7 (2.6-62.6) 42.5 (3.2-62.3) .238
Sex, n (%) .799
Male R and male D 76 (32) 38 (34) 38 (31)
Female R and male D 52 (22) 27 (24) 25 (20)
Male R and female D* 57 (24) 28 (25) 29 (24)
Female R and female D 50 (21) 19 (17) 31 (25)
Disease, n (%)
Leukemia 131 (56) 61 (54) 70 (57)
Myelodysplastic syndrome 23 (10) 12 (11) 11 (9)
Myeloproliferative syndromes 14 (6) 5 (4) 9 (7)
Chronic myelogenous leukemia 16 (7) 12 (11) 4 (3)
Chronic lymphoblastic leukemia 8 (3) 2 (2) 6 (5)
Lymphoma 19 (8) 7 (6) 12 (10)
Multiple myeloma 11 (5) 6 (5) 5 (4)
Aplastic anemia 7 (3) 4 (4) 3 (2)
Miscellaneous 6 (3) 3 (3) 3 (2)
Disease status at transplantation, n (%) .298
Complete remission 123 (52) 53 (47.3) 70 (57)
Stable disease 62 (26) 34 (30.3) 28 (23)
Progressive disease 50 (21) 25 (22.3) 25 (20)
Donor, n (%)
HLA-identical sibling 113 (48) 48 (43) 65 (53) .129
Unrelated
(10/10) HLA-identical 77 (32) 35 (31) 42 (34) .648
One-antigen HLA-mismatched 11 (5) 8 (7) 3 (2) .088
Conditioning regimen, n (%)
Myeloablative 155 (66) 82 (73) 73 (59) .028
TBI 12 Gy 93 (40) 53 (47) 40 (33)
TBI 2 Gy 67 (29) 26 (23) 41 (33)
ATG 38 (16) 18 (16) 20 (16) NS
Graft source, n (%) .033
BM 127 (54) 64 (57) 63 (51)
PBSCs 74 (31) 27 (24) 47 (38)
CB 34 (15) 21 (19) 13 (11)
CMV serology positive, n (%)
Donor 91 (39) 41 (37) 50 (41) .525
Recipient 118 (50) 56 (50) 62 (50) .950
D indicates donor; NS, not significant; R, recipient.
*Sex-mismatched graft is defined as a male recipient undergoing transplantation with cells from a female donor.
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clinical symptoms. Patients with HHV6 reactivation
were monitored weekly until a negative HHV6 PCR
test was achieved. Furthermore, specimens, such as
gut biopsies (n 5 10), cerebrospinal fluid (n 5 6),
and body cavity effusions (n 5 3), were examined for
HHV6 as clinically indicated. The frequency of testing
was not related to type of conditioning regimen or
stem cell source; the same monitoring/screening pol-
icy applied to all patients regardless of individual char-
acteristics or transplantation modality.
At the time of the present study, HHV6 PCR test-
ing was not performed routinely on the blood samples
before allo-SCT. Given the high incidence of primary
infection early in life (90% at age 18 months), we as-
sumed that virtually all of our recipients and donors
(except CB donors) could be considered seropositive
for HHV6. To determine the prevalence of positive
HHV6-PCR results in a patients not undergoing
transplantation, we routinely collected blood samples
from recipients and donors before transplantation
between September 2009 and March 2010. TheHHV6-PCR test was positive in 5 of the 58 (8.5%)
blood samples (collected from 1 donor and 4 recipi-
ents). In contrast, a positive HHV6-PCR test was ob-
served in 67% of recipients after transplantation. Two
of the 4 recipients with a positive HHV6-PCR test be-
fore allo-SCT had a positive HHV6-PCR after allo-
SCT, and further investigation confirmed HHV6
chromosomal integration in these patients.Detection of HHV6 DNA by HHV6-PCR
The technique for detecting and quantitating
HHV6 variants A and B HHV6 DNA changed during
the study period. Before January 2007, we used an in-
house, quantitative real-time PCR assay to amplify the
U65-U66 gene fragment, following the method devel-
oped by Gautheret-Dejean et al. [25]. The test was
performed on peripheral blood mononuclear cells
(PBMCs) separated from whole blood by centrifuga-
tion on Ficoll-Hypaque (Pharmacia Biotech, Uppsala,
Sweden). The PBMCs were washed, pelleted, ali-
quoted, and stored at 280C until use. DNA was
Biol Blood Marrow Transplant 18:1080-1089, 2012 1083HHV6 and Allo-SCTextracted from 200 mL of PBMC suspension using
the QiAmp Blood DNA Mini Kit (QIAGEN,
Courtaboeuf, France), in accordance with the manu-
facturer’s instructions. DNA was quantified at 260
nm with a GeneQuant spectrophotometer (Amersham
Pharmacia Biotech, Uppsala, Sweden). Amplification
of the HHV6 sequence was performed on 500 ng of
DNA extract in a Light Cycler (Roche Diagnostics,
Meylan, France). The results were reported as the
HHV6 copy number permg ofDNA, with a sensitivity
threshold of 5 copies/mg DNA.
Since January 2007, detection and quantitation of
HHV6 DNA was performed with a commercially
available real-time PCR kit (CMV HHV6, 7, 8 R-
Gene Kit; Argene, Varilhes, France). This test enables
the simultaneous quantitation of CMV and HHV6
and the qualitative detection of HHV7 and HHV8
[26]. HHV6 DNA was quantitated using a standard
curve generated with 4 quantitation standards contain-
ing 50,000, 5000, 500, and 50 copies of standard DNA
per reaction, respectively. The method was performed
on EDTA-treated whole blood. DNA was extracted
from 200 mL of EDTA whole blood using the QiAmp
Blood DNA Mini Kit (QIAGEN) in accordance with
the manufacturer’s instructions. The PCR assay was
run on an ABI Prism 7500 system (Applied Biosystems,
Courtaboeuf, France), in accordance with the manu-
facturer’s instructions. The results were reported as
HHV6 copy number per mL of whole blood, with
a sensitivity threshold of 50 copies/mL (1.70 log10).Definitions
Reactivation of HHV6 reactivation was defined as
at least 1 positive HHV6-PCR test in a whole blood
sample for each technique (ie, detection of HHV6
DNA in whole blood above each technique’s PCR sen-
sitivity threshold). Symptoms in patients with a positive
HHV6-PCR test were captured or collected from
medical file records and listed for each patient, regard-
less of cause.
HHV6 reactivation was defined as symptomatic
when no other explanatory causes were identified.
For each patient, standard etiologic investigations
were performed depending on clinical manifestations.
In patients with fever, systematic investigations in-
cluded repeat bacterial blood and stool culture plus
testing for Clostridium difficile toxin; PCR for HHV6,
EBV, CMV, and adenovirus; viral cultures of throat,
stool, and urine samples; and noninvasive tests for
fungal infections, including Aspergillus- and Candida-
specific antibody and antigen tests. Body cavity effu-
sions were subjected to systematic bacterial culture
and viral PCR. Other examinations and laboratory
tests were performed as clinically indicated.
An evaluable response to antiviral therapy was de-
fined as at least 3 consecutive negative tests after anHHV6 reactivation period of at least 1 week. HHV6
negativity was defined as the absence of detectable
PCR, and a significant decrease in the HHV6 load
was defined as a reduction of .90%.
Neutrophil engraftment was defined as achieve-
ment of an absolute neutrophil count .0.5  109/L
for 3 consecutive days (the first of which was consid-
ered the day of engraftment). Platelet engraftment
was defined as a platelet count.50 109/L for 3 con-
secutive days and no transfusion in the previous week
(with the first day considered the day of engraftment).
Statistical Analysis
Data are presented as frequencies and percentages
for categorical variables and as mean and standard de-
viation for numerical variables. Five outcome criteria
were studied: overall survival (OS), event-free survival
(EFS), nonrelapsemortality (NRM), relapse, and acute
GVHD. For the analysis of acute GVHD (grade II-IV
or grade III-IV), patients alive at day 100 post-SCT
without having experienced acute GVHD were cen-
sored. OS was defined as the probability of survival ir-
respective of disease state at any point in time, and EFS
was defined as the probability of being alive and free of
disease at any point in time. NRM was defined as the
probability of dying without previous occurrence of
a relapse (as a competing event). Relapse was defined
as the probability of experiencing a relapse before
180 days post-SCT. Death without experiencing re-
lapse was considered a competing event. After 180
days, the influence of HHV6 reactivation on patient
outcomes was considered negligible, given that immu-
nosuppressive therapy was often stopped at that point.
Thus, we focused on the early posttransplantation pe-
riod for OS, EFS, NRM, and relapse. For each analy-
sis, patients with no events at 180 days were censored.
For OS, EFS, and acute GVHD, the probability of
survival was estimated using the Kaplan-Meier
method. Reactivation of HHV6 and acute GVHD
were included as time-dependent variables in each
model. All potential risk factors were first tested in
a log-rank test. Parameters with a P value\.10 were
then introduced into a Cox proportional hazards mul-
tivariate regression analysis of survival, with stepwise
selection at P\ .10 for entry. Reactivation of HHV6
was included in each model if the P value in a bivariate
analysis was\.10. In the final model, adjusted hazard
ratio (HRs) and 95% confidence intervals (CIs) were
calculated. The proportional hazards model assump-
tion was checked using Schoenfeld residuals and the
test suggested by Therneau and Grambsch [27]. Of
note, acute GVHD and relapse were not included as
variables in the multivariate analysis, because we did
not consider factors and events occurring after trans-
plantation except, of course, HHV6 reactivation.
For NRM and relapse, cumulative incidence was
calculated using the method of Gray [28]. As noted
1084 Biol Blood Marrow Transplant 18:1080-1089, 2012R. Dulery et al.earlier, parameters with a P value \.10 were intro-
duced into the multivariate model using the method
of Fine and Gray [29].
All computations were performed using SAS
version 9.1 (SAS Institute, Cary, NC) and the cmprsk
package in R. P values\.05 were considered statisti-
cally significant.RESULTS
HHV6 Reactivation Within the First 100 Days
Post-SCT
A total of 952 HHV6 PCR tests were performed
(median of 3 tests per patient; interquartile range
[IQR], 3-5 tests). The 112 patients in group A experi-
enced early HHV6 reactivation (ie, first occurrence of
HHV6 reactivation within the first 100 days post-
SCT; median, 27 days; range, 8-91 days), whereas
the 123 patients in group B did not. Group A repre-
sented 82% of all patients with HHV6 reactivation;
25 patients experienced HHV6 reactivation after day
100 post-SCT and thus were included in group B.
Univariate analyses suggested that PBSC grafts were
protective against HHV6 reactivation. Multivariate
analysis introducing all the parameters of the univari-
ate analysis with a P value\.10 identified myeloabla-
tive conditioning as the sole risk factor for HHV6
reactivation. Other factors, including age, sex, CMV
status, donor–recipient sex mismatch, donor type, dis-
ease status at transplantation, and use of TBI and
ATG, had no significant effect on the incidence of
HHV6 reactivation (Table 1).
All but 6 (5%) of the patients in group A were
symptomatic at the time of their first positive HHV6Table 2. Symptoms Associated with HHV6 Reactivation
Group A
Patients with
Acute GVHD,
n (%)
Patients without
Acute GVHD,
n (%) P
Number of patients 112 (100) 58 (52) 54 (48)
Fever 60 (54) 30 (52) 30 (56) .685
Skin rash 57 (51) 42 (72) 15 (28) <.001
Diarrhea and/or
abdominal pain
51 (46) 21 (36) 30 (56) .040
Pulmonary
manifestations
19 (17) 9 (16) 10 (19) .672
Neurologic
disorders
12 (11) 8 (14) 4 (7) .275
Liver metabolic
disorders
8 (7) 5 (9) 3 (6) .529
Miscellaneous 8 (7) 5 (9) 3 .586
Pancytopenia 2 (2) 1 1
Graft rejection 1 (1) 0 1
Erythroblastopenia 1 (1) 0 1
Peripheral
thrombopenia
1 (1) 1 0
Fatigue (grade 3-4) 2 (2) 0 2
Myalgia 1 (1) 1 0
Ulcerative keratitis 1 (1) 1 0
Pericarditis 1 (1) 1 0test (Table 2), and 69% had multiple symptoms.
Fifty-eight group A patients were treated for acute
GVHD, 48 had GVHD-unrelated symptoms, and 6
were asymptomatic. All but 2 of these 54 patients with-
out GVHD recovered without the need for additional
immunosuppressive drugs (including steroids). One of
the 2 patients with persistent symptoms died from
EBV-associated lymphoproliferative disease at 77
days after allo-SCT, and the other died from refractory
CMV gastritis at 139 days after allo-SCT.
Twenty-one patients experienced severe complica-
tions, including encephalitis with HHV6 in the cere-
brospinal fluid (n 5 2), epileptic seizure (n 5 4),
interstitial pneumonia (n 5 7), alveolo-interstitial
pneumonia (n5 3), interstitial pneumonia plus pleural
effusion (n 5 2), and nodular pneumonia (n 5 3). No
attributed causes other than HHV6-reactivation
were identified in these patients. HHV6 was detected
in the cerebrospinal fluid of the 2 patients with enceph-
alitis, in the pleural liquid of 1 of the 2 patients with
pleural effusion, and in the bronchoalveolar lavage
(BAL) fluid of 1 of the 7 patients with interstitial pneu-
monia (note that this was the only patient tested for
HHV6 in BAL fluid).
A total of 44 patients received antiviral therapy. Of
these patients, 16 had HHV6 reactivation alone, and
17 had concurrent HHV6 and CMV infections. The
remaining 11 patients were treated for acute GVHD
before HHV6 reactivation (3 with HHV6 reactivation
alone and 8 with HHV6 and CMV reactivation).
Thirty-seven patients (84%) experienced full recovery
within a month of symptom onset.
An antiviral treatment response was observed in 34
of the 38 evaluable patients (89%), with a negative
HHV6-PCR test in 14 patients and a significantly de-
creased HHV6 load in the other 20. Of the 4 patients
who failed to achieve a negative HHV6-PCR test, 1
died of acute GVHD, 1 died of refractory cytomegalo-
virus gastritis, and 2 experienced full recovery andwere
still alive at the time of the study analysis. Moreover,
the duration of HHV6 reactivation was shorter in
the patients who received antiviral therapy compared
with those who did not (50 days versus 72 days, respec-
tively; P 5 .04).
Patient Outcomes and Engraftment
On the reference date of October 31, 2009, theme-
dian follow-up time from allo-SCT was 31 months
(range, 4-68 months). Table 3 summarizes the results
of bivariate analysis of patient outcomes. Three pa-
tients failed to achieve neutrophil engraftment, and
11 patients failed to achieve platelet engraftment.
The estimated median time to achieving a neutrophil
count of 0.5  109 cells/L was 20 days (IQR, 17-25
days), and that to achieving a platelet count of 50 
109 cells/L was 26 days (IQR, 18-43 days). In multivar-
iate analysis, HHV6 reactivation and use of ATG, an
Table 3. Bivariate Predictors of Platelet Engraftment, 180-Day OS, 180-Day EFS, Relapse, NRM, and Grade II-IV aGVHD
Initial Characteristics
Number
of Patients
Delayed Platelet
Engraftment, Days
180-Day
OFS
180-Day
EFS
180-Day
Relapse
180-Day
NRM
Grade II-IV
aGVHD
Median P % P % P % P % P % P
HHV6-PCR
Negative 123 22 <.001 89 .04 78 .10 16 -* 6 - 30 .009
Positive 112 29 79 68 22 10 47
Age of recipient, years
#45 136 - 87 .08 79 .005 14 .047 7 - 35 -
>45 99 79 63 26 9 44
Recipient sex
Male 133 - 83 - 68 .06 23 .012 8 - 38 -
Female 102 84 79 14 7 39
Donor-recipient sex match
Male R and female D 57 - 84 - 63 .04 26 .003 11 - 46 -
Other 178 83 76 17 7 36
Donor
HLA-identical siblings 115 24 <.001 92 .001 80 .02 19 - 1 .001 24 <.001
Unrelated 120 29 76 67 19 14 52
Graft source
BM 127 - 87 .09 75 - 21 - 4 .020 30 .008
PBSCs 74 80 72 16 12 45
CB 34 79 71 18 12 56
PBSCs/CB 108 80 71 17 12 48
Conditioning
Myeloablative 155 28 <.001 84 - 77 .04 15 .004 8 - 37 -
RIC 80 18 84 65 28 8 40
With ATG 38 39 .001 66 .001 58 .02 24 - 18 .007 39 -
Without ATG 197 25 87 76 18 6 38
D indicates donor; R, recipient.
The bivariate analyses introduced all initial patient characteristics (shown in Table 1) and HHV6 reactivation as a time-dependant risk factor.
*Variables with low prognostic value (P > .05) are not shown.
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found to be associated with delayed platelet engraft-
ment (Table 4 and Figure 1). HHV6 reactivation had
no impact on neutrophil engraftment. In a second
analysis, only patients with positive HHV6-PCR test
before neutrophil engraftment (n5 36) or platelet en-
graftment (n 5 65) were considered. The estimated
median time to achieving neutrophil and platelet en-
graftment was 29 days (IQR, 22.5-39.5 days) and 48Table 4. Multivariate Analyses Evaluating HHV6 Reactivation as a
Relapse, NRM, and Grade II-IV aGVHD (Hazard Ratio and Log-Ran
Delayed Platelet Engraftment Grade II-IV aGV
HR (95% CI) P HR (95% CI)
HHV6-PCR
Negative 1 1
Positive 1.60 (1.23-2.10) .001 1.59 (1.04-2.43)
Donor type
Related 1 1
Unrelated 1.72 (1.32- 2.27) <.001 2.5 (1.59-3.91)
Conditioning
RIC 1
Myeloablative 2.18 (1.64-2.90) <.001
Without ATG 1
With ATG 1.52 (1.03-2.24) .027
Recipient age, years
#45
>45 _
Significant factors (P < .10) identified in univariate analyses (Table 3) were broug
a P value <.10 were introduced into a Cox proportional hazards multivariate re
*Variables with low prognostic value (P > .05) were not retained in the final Cdays (IQR, 28-112 days), respectively, in group A ver-
sus 20 days (IQR, 16-25 days) and 22 days (IQR, 15-33
days) in group B (both P \ .001). Thus, previous
HHV6 reactivation was associated with significant de-
lays in neutrophil and platelet engraftment.
Ninety patients (38%) developed acute grade II-IV
GVHD, 56 of of whom had grade III or IV disease. In
multivariate analysis (Table 4), the most important
factors associated with the development of acute gradePredictor of Platelet Engraftment, 180-Day OS, 180-Day EFS,
k Test P Value)
HD 180-Day OS 180-Day EFS
P HR (95% CI) P HR (95% CI) P
1 1
.031 2.1 (1.05-4.03) .035 1.68 (1.01-2.79) .044
1
<.001 2.8 (1.28-6.02) .010 _*
_ _ _
1 1
_ 2.5 (1.24-5.03) .011 2.20 (1.24-3.91) .007
1 1
_ 2.1 (1.1-4.01) .025 2.22 (1.34-3.67) .002
ht intomultivariate analyses. All parameters of the bivariate analyses with
gression analysis of survival, with stepwise selection at P < .10 for entry.
ox model.
Figure 1. Platelet engraftment according to the HHV6 reactivation sta-
tus. †Mann-Whitney U test.
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95% CI, 1.04-2.43) and an unrelated donor graft
(HR, 2.5; 95% CI, 1.59-3.91). Furthermore, acute
grade III-IV GVHD was more prevalent in group A
than in group B (36% versus 13%), and occurred ear-
lier in group A (median, 32 days versus 39 days post-
transplantation; P \ .0001) (Figure 2). A second
analysis was performed after excluding the 18 patients
who developed acute GVHD before HHV6 reactiva-
tion. In multivariate analysis, the most important
factors associated with development of acute grade
III-IV GVHD were previous HHV6 reactivation
(HR, 2.09; 95% CI, 1.09-3.99) and a stem cell source
other than BM (HR, 2.70; 95% CI, 1.39-5.56). Of
note, previous CMV reactivation was not significantly
associated with the development of acute GVHD.
The 180-day OS, 180-day EFS, relapse, and NRM
rates were 84%, 73%, 19%, and 8%, respectively.
There were no significant between-group differences
in relapse and NRM. Conversely, 180-day OS was sig-
nificantly greater in group B than in group A (89% ver-
sus 79%; P5 .04). In multivariate analysis, the factorsFigure 2. Cumulative incidence of acute GVHD and log-rankmost closely associated with poor 180-day OS were
HHV6 reactivation (HR, 2.1; 95% CI, 1.05-4.03), un-
related donor graft (HR, 2.8; 95% CI, 1.28-6.02), use
of ATG (HR, 2.5; 95% CI, 1.24-5.03), and recipient
age .45 years (HR, 2.1; 95% CI, 1.1-4.01). Similarly,
the factors most strongly associated with poor 180-day
EFS were HHV6 reactivation (HR, 1.7; 95%CI, 1.01-
2.78), recipient age .45 years (HR, 2.22; 95% CI,
1.34-3.67), and use of ATG (HR, 2.20; 95% CI,
1.24-3.91). Similar results were observed when evalu-
ating 1-year OS and EFS.DISCUSSION
To the best of our knowledge, the present study is
one of the largest to date evaluating the clinical signif-
icance of HHV6 reactivation after allo-SCT. Our
findings confirm previous reports indicating that
HHV6 is a common pathogen in recipients of allo-
SCT [5-8,17,18].
Patients were monitored using an in-house PCR
technique [25] between 2004 and 2007 and a commer-
cial kit thereafter [26]. Although the results are
expressed differently for the 2 techniques, the respec-
tive detection thresholds, sensitivity, and specificity
were similar. HHV6-PCR was positive in 57 of the
113 patients tested before January 2007 and in 55 of
the 122 patients tested after January 2007 (P 5 .489).
Although a wide range of viral loads was detected
with both techniques (in-house PCR: median, 397
copies/mg DNA; range, 5-259,435 copies/mg DNA;
commercial kit: median, 2570 copies/mL; range,
50-10,440,000 copies/mL), no correlation was found
between plasma viral load and patient outcomes (ie,
number and severity of symptoms, engraftment, OS,
EFS, and incidence and severity of acute GVHD)
(data not shown). Furthermore, there was no differ-
ence in outcomes between patients with very low
HHV6 DNA loads (ie,\50 copies/mg of DNA before
January 2007 and\500 copies/mL of blood after Jan-
uary 2007) and those with higher loads.P values. (A) Grade II-IV GVHD. (B) Grade III-IV GVHD.
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as the foremost risk factor for HHV6 reactivation, as
reported previously by Chevallier et al. [30]. In con-
trast to previous reports suggesting associations
among one-antigen HLA mismatch [13,20,31], CMV
reactivation [8,13,32], TBI [33], unrelated donor graft
[18,31], and sex-mismatched graft [17] and HHV6 re-
activation, we found no such associations in the pres-
ent study. However, these previous studies were of
small series, which precluded the authors from draw-
ing firm conclusions.
Again in contrast to previous reports [19,34],
the use of BM grafts was not associated with
HHV6 reactivation in our population. However, we
observed a trend toward a protective effect of PBSCs.
The use of CB was associated with the highest rate of
HHV6 reactivation. This finding can be explained by
the absence ofHHV6-primedT cells and the immuno-
logic immaturity of CB-derived T lymphocytes
[35,36].
HHV6 reactivation translated into delayed platelet
engraftment. It is known that HHV6 can infect hema-
tologic progenitor cells and reduces colony formation
in vitro, which might explain the delayed engraftment
after allo-SCT [37,38].
Distinguishing symptoms associated with HHV6
reactivation and those due to acute GVHD is difficult.
To address this problem, we investigated symptoms in
patients with reactivated HHV6 but no acute GVHD.
This was made feasible by our policy of not initiating
additional immunosuppressive treatment in patients
with atypical symptoms (eg, isolated diarrhea and
skin rash sparing the palms and soles). Approximately
one-half of our patients had fever and/or diarrhea,
and 28% had skin rash (Table 2). In the absence of
life-threatening GVHD-like symptoms, we suggest
that a differential diagnosis of HHV6 reactivation
should be considered in patients with atypical symp-
toms. Salvage immunosuppressive treatment should
not begin until the results of viral screening and tissue
biopsy analysis are known.
Many previous researchers have reached conflict-
ing conclusions regarding the causative role of HHV6
reactivation in acute GVHD [6,17,18,21,30,39]. In
the present study, multivariate analysis revealed
a significant association between acute GVHD and
HHV6 reactivation, regardless of posttransplantation
reactivation time. Of note, this association was even
stronger for high-grade acute GVHD. The association
between viral reactivation and grade III-IV acute
GVHD remained significant in the 53% of patients
who experienced HHV6 reactivation before initiation
of salvage immunosuppression for acute GVHD. Our
findings, in agreement with others [6,17,30], suggest
that HHV6 may trigger GVHD, and that HHV6
reactivation is not triggered by immunosuppressive
therapy.It has been suggested that tissue damage caused by
the conditioning regimen and previous therapy trig-
gers the development of acute GVHD [40-42]. As
has been described for other virus reactivations [40],
the inflammatory responses to HHV6 reactivation
(ie, lytic lesions and lymphoproliferation) may accen-
tuate tissue damage [5]. Furthermore, HHV6 is
known to interfere with the immune system through
various mechanisms [43]. Monocytes and CD41 T
cells are the primary targets for HHV6 replication
[44]. During this lytic phase, HHV6 can influence
the associated immune responses and immune recon-
stitution [45,46]. Interaction with proliferating
peripheral T cells also may lead to the proliferation
and activation of alloreactive T cell clones, as has
been described in immune responses against CMV
[47]. Thus, HHV6 might directly or indirectly trigger
acute GVHD.
A clear-cut syndrome that constitutes symptomatic
HHV6 reactivation has not yet been established [2,5].
In our study population, HHV6 reactivation was
usually associated with clinical symptoms; only 5%
of the patients with a positive HHV6-PCR test were
asymptomatic. Of note, we found the same rate of
HHV6 reactivation and symptoms in patients who ex-
perienced reactivation before day 27, whenmonitoring
was more systematic, and those who did so after day 27
(the median reactivation date). Nevertheless, the inci-
dence of asymptomatic HHV6 reactivationmight have
been underestimated, given that patients with symp-
toms were more likely to be tested after discharge.
Even though no other etiology was identified,
HHV6 might not be the cause of the concomitant
symptoms in all patients. Nevertheless, the chronology
of the symptoms and the patients’ responses to antivi-
ral treatment may suggest a relationship with HHV6
reactivation. Thus, we recommend that all patients ex-
periencing such symptoms be tested for HHV6.
In our patients, HHV6 reactivation was associated
with severe clinical complications, including intersti-
tial pneumonia, pleurisy, encephalitis, and epileptic
seizures. A limitation of the present study is that
HHV6-PCR analysis was seldom performed on tissue
biopsy specimens, body cavity effusions, or BAL fluid.
However, the few tests that were performed generally
demonstrated positivity for HHV6. Based on those
findings, we suggest that tissue biopsy analysis should
be performed as often as possible to identify possible
differences in viral load between blood and tissues,
which could be useful information.
With the exception of encephalitis [48], the criteria
for initiating antiviral therapy for HHV6-related man-
ifestations are not well established. In the present
study, full symptomatic recovery was observed in
84% of treated patients within 1 month, and a signifi-
cant decrease in HHV6-PCR viral load was docu-
mented in 89% of evaluable cases. Although this
1088 Biol Blood Marrow Transplant 18:1080-1089, 2012R. Dulery et al.study was not designed to evaluate the efficacy of anti-
HHV6 treatment, the duration of HHV6 reactivation
was shorter in patients who received antiviral therapy
compared with those who did not.
The exact etiologic role of HHV6 reactivation in
the increased morbidity and mortality after allo-SCT
remains unclear. However, in contrast to other authors
[30,39], we found no significant impact of HHV6
reactivation on NRM in our cohort. This discrepancy
might be related to the greater number of patients
analyzed and the lower NRM (7.5% at 6 months and
12% at 12 months) in our study.
In conclusion, our findings indicate that 2 factors
seem to protect against HHV6-reactivation: use of
PBSC grafts andRIC. EarlyHHV6 reactivation is usu-
ally symptomatic and associated with delayed platelet
engraftment, development of acute GVHD, and early
mortality. Because several HHV6-related clinical
symptoms can be suggestive of acute GVHD, careful
monitoring of HHV6 viral load is important. In pa-
tients with atypical, non–life-threatening GVHD-like
symptoms, a differential diagnosis of HHV6 reactiva-
tion should be considered. With the ongoing goal of
reducing HHV6-related morbidity and mortality, fur-
ther studies are needed to elucidate the relationship be-
tween the causative role of HHV6 reactivation and its
clinical manifestations and to investigate the efficacy of
available therapeutic approaches.ACKNOWLEDGMENTS
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